000			01863 a2200529 4500
005			20250516051227.0
264		0	_c20120206
008			201202s 0 0 eng d
022			_a1878-5921
024	7		_a10.1016/j.jclinepi.2011.04.009 _2doi
040			_aNLM _beng _cNLM
100	1		_aSuissa, Daniel
245	0	0	_aNumber needed to treat is incorrect without proper time-related considerations. _h[electronic resource]
260			_bJournal of clinical epidemiology _cJan 2012
300			_a42-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAcyclovir _xanalogs & derivatives
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aData Interpretation, Statistical
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aEvidence-Based Medicine
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHerpes Simplex _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLife Tables
650	0	4	_aPeriodicals as Topic
650	0	4	_aRandomized Controlled Trials as Topic _xstandards
650	0	4	_aResearch Design
650	0	4	_aRisk Assessment _xstatistics & numerical data
650	0	4	_aRisk Factors
650	0	4	_aSample Size
650	0	4	_aSurvival Rate
650	0	4	_aTime Factors
650	0	4	_aValacyclovir
650	0	4	_aValine _xanalogs & derivatives
650	0	4	_aZoledronic Acid
700	1		_aBrassard, Paul
700	1		_aSmiechowski, Brielan
700	1		_aSuissa, Samy
773	0		_tJournal of clinical epidemiology _gvol. 65 _gno. 1 _gp. 42-6
856	4	0	_uhttps://doi.org/10.1016/j.jclinepi.2011.04.009 _zAvailable from publisher's website
999			_c21061650 _d21061650